{"id":129307,"date":"2021-07-05T13:06:39","date_gmt":"2021-07-05T05:06:39","guid":{"rendered":"http:\/\/www.namnewsnetwork.org\/?p=129307"},"modified":"2021-07-05T13:06:43","modified_gmt":"2021-07-05T05:06:43","slug":"parexel-to-be-acquired-by-eqt-private-equity-and-goldman-sachs-asset-management","status":"publish","type":"post","link":"http:\/\/namnewsnetwork.org\/?p=129307","title":{"rendered":"Parexel to be Acquired by EQT Private Equity and Goldman Sachs Asset Management"},"content":{"rendered":"\n<p><strong>BOSTON and DURHAM, N.C., July 5 (Bernama<strong>-GLOBE NEWSWIRE<\/strong>) &#8212; <\/strong>Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, today announced the execution of a definitive merger agreement under which it will be acquired by EQT IX fund (\u201cEQT Private Equity\u201d) and the Private Equity business within Goldman Sachs Asset Management (\u201cGoldman Sachs\u201d) from Pamplona Capital Management LP for $8.5 billion.<\/p>\n\n\n\n<p>\u201cOver the past 18 months Parexel has continued its strong growth trajectory delivering on its patients-first focus and accelerating new therapies to patients in need around the world,\u201d said Parexel CEO Jamie Macdonald. \u201cWith the market for outsourced clinical research services anticipated to grow at a conservative CAGR of 8 to 9 percent, our focus remains on advancing and innovating Parexel to meet our customers\u2019 needs across the evolving clinical development landscape. EQT and Goldman Sachs support this vision and are committed to investing in Parexel and our people to capitalize on this exciting market opportunity and make a difference for patients.\u201d<\/p>\n\n\n\n<p><a href=\"http:\/\/mrem.bernama.com\/viewsm.php?idm=40457\">http:\/\/mrem.bernama.com\/viewsm.php?idm=40457<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON and DURHAM, N.C., July 5 (Bernama-GLOBE NEWSWIRE) &#8212; Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, today announced the execution of a definitive merger agreement under which it will be acquired by EQT IX fund (\u201cEQT Private Equity\u201d) and the Private [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[315],"tags":[],"_links":{"self":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/129307"}],"collection":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=129307"}],"version-history":[{"count":0,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/129307\/revisions"}],"wp:attachment":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=129307"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=129307"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=129307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}